NEW YORK, Oct. 11, 2012 \/PRNewswire\/ --Reportlinker.com announces that a new market research report is available in its catalogue: <\/p>\n
http:\/\/www.reportlinker.com\/p01009677\/Nanoparticles-in-Biotechnology-Drug-Development-and-Drug-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechnology<\/a> <\/p>\n REPORT HIGHLIGHTS <\/p>\n -The global market for nanoparticles in biotechnology, drug development and drug delivery was valued at $17.5 billion in 2011 and should reach nearly $21.6 billion in 2012. Total market value is expected to reach $53.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.9%.-Drug delivery systems are expected to increase from $11.3 billion in 2012 to $30.9 billion in 2017, a CAGR of 22.2%.-Drug development and formulation should total nearly $9.4 billion in 2012 and nearly $20.5 billion in 2017, a CAGR of 16.9%. <\/p>\n STUDY GOALS AND OBJECTIVES <\/p>\n This study provides a comprehensive analysis of the market for nanoparticles in the life sciences on a global basis. Particular attention is given to drug development and formulation and the development of new drug delivery systems. Its aim is to provide a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends in order to quantify and qualify the market for drug products for treating various disease conditions in both men and women. The applicability of specific types of nanoparticles for specific applications is discussed. <\/p>\n Forecasts and trends are developed from a cross-reference of data points gleaned from proprietary industry sources, company publications, industry benchmarking and other divergent data sources to arrive at a cogent and coordinated forecast. <\/p>\n The nanoparticle drug\/delivery market presents an increasingly significant part of the overall pharmaceutical product market worldwide. This study investigates the specific classes of nanoparticles and the pharmaceutical products associated with them. Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed. Growing health concerns in developing countries are expected to continue to contribute substantially to market growth through the forecast period (2012 through 2017). This report analyzes emerging markets by technology category. Continued growth is expected in emerging geographies driven by the health awareness of the growing middle class in emerging countries such as India, China, Brazil and Russia.This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and products, strategies for accessing emerging markets and awareness of specific disease prevalence and geographies thereof in order to allocate resources and make effective decisions. <\/p>\n SCOPE OF REPORT <\/p>\n Current and projected product forecasts during the forecast period of 2012 through 2017 are discussed. New product launches will be discussed. Revenue figure for 2011 are in an actual figures except where actual results have not been reported due to the timing of this report's release. <\/p>\n<\/p>\n Read the original: NEW YORK, Oct. 11, 2012 \/PRNewswire\/ --Reportlinker.com announces that a new market research report is available in its catalogue: http:\/\/www.reportlinker.com\/p01009677\/Nanoparticles-in-Biotechnology-Drug-Development-and-Drug-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechnology<\/a> REPORT HIGHLIGHTS -The global market for nanoparticles in biotechnology, drug development and drug delivery was valued at $17.5 billion in 2011 and should reach nearly $21.6 billion in 2012. Total market value is expected to reach $53.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.9%.-Drug delivery systems are expected to increase from $11.3 billion in 2012 to $30.9 billion in 2017, a CAGR of 22.2%.-Drug development and formulation should total nearly $9.4 billion in 2012 and nearly $20.5 billion in 2017, a CAGR of 16.9%. Continue reading
\nNanoparticles in Biotechnology, Drug Development and Drug Delivery<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"